GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » Debt-to-EBITDA

Abaxis (Abaxis) Debt-to-EBITDA : 0.00 (As of Mar. 2018)


View and export this data going back to 1992. Start your Free Trial

What is Abaxis Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abaxis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2018 was $0.0 Mil. Abaxis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2018 was $0.2 Mil. Abaxis's annualized EBITDA for the quarter that ended in Mar. 2018 was $57.1 Mil. Abaxis's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2018 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Abaxis's Debt-to-EBITDA or its related term are showing as below:

ABAX's Debt-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.96
* Ranked among companies with meaningful Debt-to-EBITDA only.

Abaxis Debt-to-EBITDA Historical Data

The historical data trend for Abaxis's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis Debt-to-EBITDA Chart

Abaxis Annual Data
Trend Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 -

Abaxis Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

Competitive Comparison of Abaxis's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Abaxis's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abaxis's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abaxis's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Abaxis's Debt-to-EBITDA falls into.



Abaxis Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abaxis's Debt-to-EBITDA for the fiscal year that ended in Mar. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.177) / 46.661
=0.00

Abaxis's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.177) / 57.072
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2018) EBITDA data.


Abaxis  (NAS:ABAX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Abaxis Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Abaxis's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Abaxis (Abaxis) Business Description

Traded in Other Exchanges
N/A
Address
Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.
Executives
Richard Bastiani director C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr officer: CFO and VP of Finance C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson director, officer: CEO & Board Chairman C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020